{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:26:35Z","timestamp":1768281995821,"version":"3.49.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:00:00Z","timestamp":1464912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["NCT02123433"],"award-info":[{"award-number":["NCT02123433"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0156523","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T13:44:50Z","timestamp":1464961490000},"page":"e0156523","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study"],"prefix":"10.1371","volume":"11","author":[{"given":"Francesca","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Belmonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacinta","family":"Tordini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Cauda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,6,3]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/infdis\/173.4.857","article-title":"Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients","volume":"173","author":"KA Gebo","year":"1996","journal-title":"The Journal of infectious diseases"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/QCO.0b013e328012c5f1","article-title":"HIV and pneumococcal disease","volume":"20","author":"KP Klugman","year":"2007","journal-title":"Current opinion in infectious diseases"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/QAI.0b013e3181e8ed15","article-title":"Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine","volume":"55","author":"AP Kourtis","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/339882","article-title":"Recurrent invasive pneumococcal disease in individuals with human immunodeficiency virus infection","volume":"185","author":"MC McEllistrem","year":"2002","journal-title":"The Journal of infectious diseases"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1086\/420933","article-title":"Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy","volume":"38","author":"Q Jordano","year":"2004","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"e27929","DOI":"10.1371\/journal.pone.0027929","article-title":"Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program","volume":"6","author":"MC Nunes","year":"2011","journal-title":"PloS one"},{"key":"ref7","article-title":"Recommendations of the Immunizations Practices Advisory Committee: Pneumococcal polysaccharide vaccine","volume":"38","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40266-013-0060-5","article-title":"Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice","volume":"30","author":"A Vila-Corcoles","year":"2013","journal-title":"Drugs & aging"},{"issue":"14","key":"ref9","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.vaccine.2005.12.021","article-title":"Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study","volume":"24","author":"V Falco","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1468-1293.2009.00744.x","article-title":"A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy","volume":"11","author":"CC Hung","year":"2010","journal-title":"HIV medicine"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/172.5.1253","article-title":"Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine","volume":"172","author":"F Mascart-Lemone","year":"1995","journal-title":"The Journal of infectious diseases"},{"issue":"9221","key":"ref12","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(00)02377-1","article-title":"23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial","volume":"355","author":"N French","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"T Pilishvili","year":"2010","journal-title":"The Journal of infectious diseases"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"EA Clutterbuck","year":"2012","journal-title":"The Journal of infectious diseases"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jinf.2014.06.006","article-title":"Review: current and new generation pneumococcal vaccines","volume":"69","author":"C Feldman","year":"2014","journal-title":"The Journal of infection"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJMoa0903029","article-title":"A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults","volume":"362","author":"N French","year":"2010","journal-title":"The New England journal of medicine"},{"issue":"37","key":"ref17","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1016\/j.vaccine.2013.04.065","article-title":"Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil","volume":"31","author":"YL Ho","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.vaccine.2014.01.009","article-title":"Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy","volume":"32","author":"CL Lu","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"LG Rubin","year":"2014","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"34","key":"ref20","first-page":"1102","article-title":"Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref21"},{"key":"ref22","article-title":"Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine","author":"S Belmonti","year":"2015","journal-title":"Journal of immunoassay & immunochemistry"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/CVI.05252-11","article-title":"Establishment of a new human pneumococcal standard reference serum, 007sp","volume":"18","author":"D Goldblatt","year":"2011","journal-title":"Clinical and vaccine immunology: CVI"},{"key":"ref24","unstructured":"World Health Organization. Recommendation for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series. No. 927, 2005."},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/01.inf.0000237830.33228.c3","article-title":"Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy","volume":"25","author":"MJ Abzug","year":"2006","journal-title":"The Pediatric infectious disease journal"},{"issue":"14","key":"ref26","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1097\/QAD.0000000000000385","article-title":"Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection","volume":"28","author":"A Bamford","year":"2014","journal-title":"AIDS"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"NJ Andrews","year":"2014","journal-title":"The Lancet infectious diseases"},{"issue":"35","key":"ref28","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1016\/j.vaccine.2011.06.072","article-title":"The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children","volume":"29","author":"C Thanee","year":"2011","journal-title":"Vaccine"},{"key":"ref29","article-title":"Sage university paper series on quantitative applications in the social sciences, 07\u2013084","author":"ER Girden","year":"1992"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF02289823","article-title":"On methods in the analysis of profile data","volume":"24","year":"1959","journal-title":"Psychometrika"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/infdis\/jiu631","article-title":"Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine","volume":"212","author":"MJ Glesby","year":"2015","journal-title":"The Journal of infectious diseases"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/QAD.0000000000000689","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination","volume":"29","author":"AE Bhorat","year":"2015","journal-title":"AIDS"},{"key":"ref33","unstructured":"European Medicine Agency (EMA). Prevenar13: Summary of product characteristics. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001104\/WC500057247.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001104\/WC500057247.pdf<\/ext-link>. Last accessed 28\/04\/2015."},{"key":"ref34","unstructured":"CADTH Rapid Response Reports. Conjugate Pneumococcal Vaccine (13-Valent) for Immunocompromised Populations: A Review of the Clinical Evidence [<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0071582\/pdf\/TOC.pdf\" xlink:type=\"simple\">http:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0071582\/pdf\/TOC.pdf<\/ext-link>]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Mar."},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11908-013-0326-4","article-title":"Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines","volume":"15","author":"C Munoz-Almagro","year":"2013","journal-title":"Current infectious disease reports"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/173.1.83","article-title":"Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial","volume":"173","author":"F Ahmed","year":"1996","journal-title":"The Journal of infectious diseases"},{"issue":"3\u20134","key":"ref37","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0264-410X(01)00347-4","article-title":"Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and\/or 23-valent polysaccharide vaccine among HIV-infected adults","volume":"20","author":"DR Feikin","year":"2001","journal-title":"Vaccine"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0156523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T07:11:22Z","timestamp":1540278682000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0156523"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,3]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0156523","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,3]]}}}